FIGURE 1 from Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib
Ida H., Shimizu T., Nishino M., Nakamura Y., Yazaki S., Katsuya Y., Sato J., Koyama T., Iwasa S., Sudo K., Kondo S., Yonemori K., Shitara K., Shiono S., Matsuoka D., Yasuda K., Otake Y., Suzuki T., Takase T., Takashima S., Yamaguchi K., Semba T., Yamamoto N.
<p>Maximum percentage change from baseline in sums of tumor diameters and best overall response per RECIST v1.1. E7389-LF, eribulin liposomal formulation; PD, progressive disease; PR, partial response; Q#W, every # weeks; RECIST v1.1, Response Evaluation Criteria In Solid Tumors, version 1.1; SD, stable disease.</p>